Replies to post #223784 on Biotech Values

[mcbio]

Re: ASMB

Thanks. I'm still holding a smaller position in this one (actually my smallest holding). I still don't trust how the stock will react to the P2 data for the lead drug next Q. I'm typically a bit wary when companies have multiple next-gen versions of a lead drug right behind in development as it just makes me wonder if the lead drug won't be sufficient. Keeping a bit of dry powder to potentially add big if there is any significant sell-off.

[mcbio]

ASMB @ Jefferies HBV summit (3/18/19)

I just listened to the ASMB presentation at this conference and the CEO stated that they will soon have a 4th and possibly even 5th CpAM drug in development for HBV. With P2 data due for their lead CpAM next quarter, I can't say this exactly inspires a lot of confidence. What is wrong with the first 3 CpAMs for HBV? I can honestly say I've never seen a lead drug already being developed over so many times so early in its development.

[DewDiligence]

ASMB 1Q19 results—3/31/19 cash=$193.5M; 1Q19 burn=$24.6M:

https://www.globenewswire.com/news-release/2019/05/09/1821361/0/en/Assembly-Biosciences-Reports-First-Quarter-2019-Financial-Results-and-Recent-Highlights.html

ASMB is a competitor of ENTA in HBV (#msg-148672065).